Yo Shaun, Thenganatt John, Lipton Jeffrey, Granton John
Division of Respirology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
Pulm Circ. 2020 Aug 21;10(3):2045894020936913. doi: 10.1177/2045894020936913. eCollection 2020 Jul-Sep.
Pulmonary arterial hypertension is associated with tyrosine kinase inhibitors used in the treatment of chronic myeloid leukemia. Dasatinib is a known cause of drug-induced pulmonary arterial hypertension. There have been case reports linking Bosutinib with deterioration of pre-existing pulmonary arterial hypertension. Here, we present a case of a 37-year-old woman with chronic myeloid leukemia treated with Bosutinib who was diagnosed with pulmonary arterial hypertension. Prior to Bosutinib, she had received Dasatinib without documented cardiopulmonary toxicity. Withdrawal of Bosutinib led to partial reversal of pulmonary arterial hypertension, and with the addition of pulmonary arterial hypertension-targeted treatment, there was near normalization of hemodynamics.
肺动脉高压与用于治疗慢性髓性白血病的酪氨酸激酶抑制剂有关。达沙替尼是药物性肺动脉高压的已知病因。已有病例报告将博舒替尼与原有肺动脉高压的恶化联系起来。在此，我们报告一例37岁患有慢性髓性白血病的女性，她接受博舒替尼治疗后被诊断为肺动脉高压。在使用博舒替尼之前，她曾接受达沙替尼治疗，但未记录有心肺毒性。停用博舒替尼导致肺动脉高压部分逆转，并且在加用肺动脉高压靶向治疗后，血流动力学接近正常。
